Aptevo Reports 21% of AML Patients Advance to Stem Cell Transplant After Mipletamig Combination Therapy

• Aptevo Therapeutics reported 10 of 47 evaluable frontline acute myeloid leukemia patients, or 21%, advanced to potentially curative stem cell transplantation.
• Patients initially deemed unfit for intensive chemotherapy received mipletamig with venetoclax and azacitidine.
• Transplant recipients included nine RAINIER trial patients and one dose-expansion patient.
• The historical VIALE-A transplant rate with venetoclax and azacitidine alone was 0.7%; differences between trials limit comparisons.
• RAINIER dose optimization is expected to conclude by year-end 2026, with FDA discussions and Phase 2 initiation anticipated in first-half 2027.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Aptevo Therapeutics Inc. published the original content used to generate this news brief on October 26, 2026, and is solely responsible for the information contained therein.